Literature DB >> 10915084

In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease.

C Fiuza1, M Salcedo, G Clemente, J M Tellado.   

Abstract

Bacterial infections are frequent, life-threatening complications in cirrhotic patients. This study investigated in vivo neutrophil migration and phagocytic activity in cirrhotic patients with advanced liver disease, in liver transplant recipients, and in healthy volunteers, by use of the skin window technique. Complement receptor type III (CR3) expression was also measured in blood and elicited neutrophils. Neutrophil migration to skin windows and neutrophil in vivo phagocytosis of heat-killed Escherichia coli were significantly decreased in cirrhotic patients compared with healthy controls. Neutrophil migration and phagocytosis were decreased in cirrhotic patients with previous episodes of bacterial infection compared with noninfected patients. Expression of CR3 in circulating neutrophils was significantly higher in cirrhotic patients, whereas it was significantly reduced in elicited neutrophils of cirrhotic patients with previous bacterial infection. These data suggest that deficient neutrophil recruitment to the infection site and impaired phagocytic activity may contribute to bacterial infections in cirrhotic patients with advanced liver disease.

Entities:  

Mesh:

Year:  2000        PMID: 10915084     DOI: 10.1086/315742

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  60 in total

1.  Early events in spontaneous bacterial peritonitis.

Authors:  B A Runyon
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

2.  Vitamin D status and expression of vitamin D receptor and LL-37 in patients with spontaneous bacterial peritonitis.

Authors:  Chong Zhang; Lianrong Zhao; Li Ma; Cheng Lv; Yang Ding; Tingting Xia; Jingyan Wang; Xiaoguang Dou
Journal:  Dig Dis Sci       Date:  2011-07-14       Impact factor: 3.199

3.  Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis.

Authors:  Anatol Panasiuk; Jolanta Wysocka; Elzbieta Maciorkowska; Bozena Panasiuk; Danuta Prokopowicz; Janusz Zak; Karol Radomski
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

4.  Renal and Gastrointestinal Considerations in Joint Replacement Surgery.

Authors:  Benjamin Voss; Alexander Kurdi; Alexander Skopec; Jasmine Saleh; Mouhanad M El-Othmani; Joseph M Lane; William M Mihalko; Khaled J Saleh
Journal:  J Nat Sci       Date:  2015-02-01

5.  Risk factors for mortality in cirrhotic patients with sepsis.

Authors:  Lee-Guan Lim; Xiang-Xuan Eunice Tan; Shu-Jeng Woo; Yock-Young Dan; Yin-Mei Lee; Vincent Lai; Seng-Gee Lim
Journal:  Hepatol Int       Date:  2011-02-13       Impact factor: 6.047

6.  Protective role of quercetin against hematotoxic and immunotoxic effects of furan in rats.

Authors:  Rasha T Alam; Ehsan H Abu Zeid; Tamer S Imam
Journal:  Environ Sci Pollut Res Int       Date:  2016-11-26       Impact factor: 4.223

7.  Dysfunction of Circulating Polymorphonuclear Leukocytes and Monocytes in Ambulatory Cirrhotics Predicts Patient Outcome.

Authors:  Konstantina Sargenti; Åsa Johansson; Sara Bertilsson; Inger Mattsby-Baltzer; Daniel Klintman; Evangelos Kalaitzakis
Journal:  Dig Dis Sci       Date:  2016-03-24       Impact factor: 3.199

8.  High seroprevalence of human herpesvirus type 8 infection in males with advanced lung carcinoma.

Authors:  Cheng-Chuan Su; Chun-Liang Lai; Shih-Ming Tsao; Ming-Nan Lin; Tang-Yuan Chu
Journal:  Med Microbiol Immunol       Date:  2014-08-15       Impact factor: 3.402

Review 9.  Impairment of innate immune responses in cirrhotic patients and treatment by branched-chain amino acids.

Authors:  Ikuo Nakamura
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  High seroprevalence of human herpesvirus type 8 in patients with hepatocellular carcinoma.

Authors:  C-C Su; K-C Tseng; M-N Lin; T-C Hsieh; T-Y Chu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-20       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.